-=Edwards Lifesciences (EW) reported earnings on Thur 1 Feb 2018 (a/h)

Edwards Lifesciences beats by $0.03, beats on revs; guides Q1 EPS above consensus, revs above consensus; guides FY18 EPS above consensus, revs in-line

• Reports Q4 (Dec) earnings of $0.94 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $0.91; revenues rose 15.7% year/year to $888.5 mln vs the $868.45 mln Capital IQ Consensus.
• "Our strong 2017 reinforces our confidence in our focused innovation strategy and longer term outlook, and we look forward to an exciting 2018 as we continue to aggressively invest in our future. We expect to achieve a number of important milestones supporting progress in the development of transformative therapies across all of our product lines. Our differentiated strategy continues to benefit patients and serve us well as we plan for future growth and value creation."
• Co issues upside guidance for Q1, sees EPS of $1.04-1.14, excluding non-recurring items, vs. $1.04 Capital IQ Consensus Estimate; sees Q1 revs of $900-950 mln vs. $904.98 mln Capital IQ Consensus Estimate.
• Co issues guidance for FY18, sees EPS of $4.43-4.63, excluding non-recurring items, vs. $4.27 Capital IQ Consensus Estimate; sees FY18 revs of $3.5-3.9 bln vs. $3.74 bln Capital IQ Consensus Estimate.